Brian’s 32+ year career in the healthcare and life sciences industries has prepared him well to lead Remi Therapeutics. Serving in C-suite roles including CEO, COO, and CCO he has an extensive background in clinical development, product commercialization, global sales strategy and delivery, business development and operations. Brian’s experience encompasses the full product and business life cycle, from pre-clinical to clinical, approval, market access and commercial launch. He has led business development activities that have resulted in agreements with partners across the globe. As a C-suite executive Brian has been instrumental in the raise of over a $100 million to support clinical development and commercial activities. During his career he has participated in the launch of 30 products, some with sales that exceeding $1billion in annual sales. Brian’s previous roles include senior executive leadership positions with start-up medical device, biotech and pharma companies. He has held senior executive positions at Veru Inc., Telesta Therapeutics, Horizon, Dendreon, Novartis and Merck & Co. He holds a Masters Degree in Healthcare Administration and Marketing, as well as a B.S. in Physiology, both from Central Michigan University.

Bobbie’s experience in life sciences operations encompasses SEC Reporting, internal controls, compliance, cash management, budgeting and forecasting, analytics, distribution, customer contracting and sales reporting. Most recently, she served as Chief Financial Officer, helping and early-stage digital therapeutic company develop and implement accounting policies and procedures along with assisting the company in fundraising efforts. Previously Bobbie worked at Shield Therapeutics as Vice President, Commercial and Sales Operations for responsible for setting up U.S. Operations including financial reporting, internal controls, human resources along with distribution, gross-to-net reporting and various other tasks. She also worked for Veru Inc., where she was responsible for establishing the company’s commercial infrastructure, building a proprietary CRM, and creating a scalable sales organization. While at Veru, she served in various accounting roles including Financial Controller, responsible for SEC reporting, financial consolidation, internal controls and U.S. Operations. Previously, she held the role of Material Manager for MGS Mfg. Group Inc., responsible for the profit/loss of two plastics manufacturing facilities. Bobbie holds an B.S. in Accounting from Marquette University.

Anil is an entrepreneur who has dedicated his career to drug development for mental illnesses. He is currently Executive Director and Founder of Amyriad Therapeutics B.V., a company developing a Phase 3 program for a candidate drug for dementia in Alzheimer’s disease. He is also the Founder of Cennerv Pharmaceuticals Ltd, Singapore, which focused on developing early-stage drug candidates. Previously Anil was Executive Director and Chief Scientific Officer of Cerca Insights Sdn Bhd, a company in the business of providing animal behaviour phenotyping services. Prior, Anil founded Chakra Biotech, a company involved in the discovery and development of drug candidates for various mental illnesses using animal behaviour phenotyping. He also served as Executive Director and Chief Executive Officer of Cicada Cube Pte Ltd which was in the business of software engineering for the development of enterprise search products and healthcare information technology products. Anil was a regional director of Fisher Scientific (SEA) Pte Ltd, a subsidiary of Thermo Fisher Scientific Pte Ltd, where he established the biotech business unit for South-East Asia, developed the distribution and logistics business for Fisher Scientific (SEA) Pte Ltd in India, Pakistan and Sri Lanka, and was a member of the Fisher Science and Technology Council in USA.

Jon has been doing clinical pharmacology research full time since 1995. He has served as the Medical Director for Clinical Research Units in Tacoma WA (Northwest Kinetics, Comprehensive Clinical Research) and Honolulu HI (Radiant Research, Covance), and was Principal Investigator for over 350 clinical trials, mostly Phase I. He founded Pacific Pharma Group, LLC in 2008. He has provided medical monitoring and consulting services regarding product development strategy and study design for over 200 clinical trials, mostly Phase I. He has served as the Chief Medical Officer for Inimmune, Inc. since January 2022. His experience as an investigator and consultant spans a wide range of compounds, clinical indications, and pharmaceutical sponsors worldwide, mostly in the space from first-in-humans through proof-of-concept. He is an alumnus of Loma Linda University School of Medicine, completed his residency in Internal Medicine at the Mayo Clinic in Rochester, MN, is board certified in Internal Medicine, is a Certified Physician Investigator, and an Authorized User for 14C radiolabeled microdose and ADME studies. His research experience follows a primary care medical practice 1984 to 1995. He maintains current medical licenses in both Washington and Hawaii.

John has more than twenty-five years of management, operations, clinical research, product sales, and technical consulting experience spanning the biopharma and life science industries. Most recently, he served as VP of Biopharma Partnerships at Tasso Inc., a medical device company specializing in patient-centric blood collection technology. Prior to Tasso, John was VP Market Development & Medical Affairs for both Shield Therapeutics and Acasti Pharma, helping to launch a small molecule oral product with FDA approval at Shield. John previously held the position of Chief Business Development Officer at AMR Inc, a multi-site clinical research company. In addition to his biopharma and site network corporate experience, he spent more than five years at one of the world’s largest CROs, PPD Inc., managing both sales and operations teams across the company. During his five years with Comprehensive Neuroscience, he was VP and General Manager of the CRO division. John earned his doctorate from the University of Texas at Austin, College of Pharmacy (Pharmacology & Toxicology Division). He holds undergraduate and graduate engineering degrees from the Colorado School of Mines. He has served on two institutional review boards (IRBs).

Tim is the founder of Life Science Compliance Consulting, LLC. He serves as both General Counsel and Compliance Officer. Previously, he was the Chief Compliance Officer for Horizon Pharma plc. He has held various legal and compliance roles at small biotech companies, starting his in-house work at Pfizer in 2004. Prior to joining the in-house ranks, Mr. Ayers was an attorney in the healthcare group for the Washington, DC Office of Winston & Strawn, LLP. Mr. Ayers is a graduate of Georgetown University, where he also obtained his J.D. in 1998. He subsequently obtained his Masters in Public Health from Columbia University in 2000.